Geometric Mean Titre( 1 / dil) of DENV-1 neutralizing antibodies in Test and Control Groups | |||||||
DENV 1 |
Dayan, et al |
HSS, et al |
Lanata, et al |
Sabchareon, et al |
Villar, et al |
Leo, et al
( 2-11)
|
Leo, et al
( 12-17)
|
Baseline( Test Group) |
41.4 |
15.3 |
17.4 |
42.8 |
74.2 |
5.33 |
6.47 |
Post Dose 2( Test Group) |
436 |
119 |
125 |
120.7 |
276 |
- |
- |
Post Dose 3( Test Group) |
267 |
151 |
179 |
146.1 |
320 |
56.6 |
28.5 |
Baseline( Control Group) |
47.2 |
18.6 |
22.8 |
26.6 |
81.9 |
5.42 |
5.47 |
Post Dose 2( Control Group) |
130 |
21 |
26.4 |
21.9 |
102 |
- |
- |
Post Dose 3( Control Group) |
79.2 |
18.9 |
38.1 |
23.9 |
106 |
6.06 |
6.36 |
Geometric Mean Titre( 1 / dil) of DENV-2 neutralizing antibodies in Test and Control Groups | |||||||
DENV 2 |
Dayan, et al |
HSS, et al |
Lanata, et al |
Sabchareon, et al( 2012) |
Villar, et al |
Leo, et al
( 2-11)
|
Leo, et al
( 12-17)
|
Baseline( Test Group) |
67 |
15.9 |
14.4 |
56.8 |
92.6 |
5.85 |
7.45 |
Post Dose 2( Test Group) |
647 |
160 |
151 |
326 |
504 |
||
Post Dose 3( Test Group) |
544 |
180 |
178 |
310 |
486 |
101 |
48.7 |
Baseline( Control Group) |
68.3 |
18.6 |
18.2 |
43.7 |
100 |
5.17 |
5.54 |
Post Dose 2( Control Group) |
137 |
17.9 |
17.3 |
43.5 |
114 |
||
Post Dose 3( Control Group) |
132 |
16.3 |
21.6 |
52.2 |
133 |
5.88 |
6.17 |
Geometric Mean Titre( 1 / dil) of DENV-3 neutralizing antibodies in Test and Control Groups | |||||||
DENV 3 |
Dayan, et al |
HSS, et al |
Lanata, et al |
Sabchareon, et al( 2012) |
Villar, et al |
Leo, et al
( 2-11)
|
Leo, et al
( 12-17)
|
Baseline( Test Group) |
81.9 |
15.6 |
16.4 |
31.5 |
85 |
6.24 |
6.84 |
Post Dose 2( Test Group) |
1031 |
196 |
155 |
195 |
502 |
||
Post Dose 3( Test Group) |
741 |
193 |
190 |
405 |
594 |
136 |
71.4 |
Baseline( Control Group) |
94.7 |
15.9 |
21.8 |
28.7 |
88.8 |
5.95 |
6.83 |
Post Dose 2( Control Group) |
227 |
15.9 |
26.6 |
24.6 |
108 |
||
Post Dose 3( Control Group) |
140 |
16.3 |
36.2 |
48.9 |
121 |
6.54 |
8.1 |
Geometric Mean Titre( 1 / dil) of DENV-4 neutralizing antibodies in Test and Control Groups | |||||||
DENV 4 |
Dayan, et al |
HSS, et al |
Lanata, et al |
Sabchareon, et al( 2012) |
Villar, et al |
Leo, et al
( 2-11)
|
Leo, et al
( 12-17)
|
Baseline( Test Group) |
15 |
9.92 |
8.12 |
28.1 |
37.2 |
5.64 |
5.83 |
Post Dose 2( Test Group) |
346 |
110 |
144 |
159 |
305 |
||
Post Dose 3( Test Group) |
432 |
114 |
184 |
155 |
276 |
104 |
79.2 |
Baseline( Control Group) |
17.5 |
12.3 |
8.94 |
23.2 |
40.1 |
5.39 |
5.08 |
Post Dose 2( Control Group) |
31.2 |
13.3 |
12.8 |
21.2 |
43.9 |
||
Post Dose 3( Control Group) |
33.4 |
10.9 |
16.7 |
19.4 |
42.8 |
7.2 |
6.45 |